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Abstract
The present study was designed to determine the biological effects of novel marine alkaloid analog 7-(4-
fluorobenzylamino)-1,3,4,8-tetrahydropyrrolo[4,3,2-de]quinolin-8(1H)-one (FBA-TPQ) on human ovarian cancer cells for its
anti-tumor potential and the underlying mechanisms as a novel chemotherapeutic agent. Human ovarian cancer cells
(A2780 and OVCAR-3), and Immortalized non-tumorigenic human Ovarian Surface Epithelial cells (IOSE-144), were exposed
to FBA-TPQ for initial cytotoxicity evaluation (via MTS assay kit, Promega). The detailed in-vitro (cell level) and in-vivo (animal
model) studies on the antitumor effects and possible underlying mechanisms of action of the compounds were then
performed. FBA-TPQ exerted potent cytotoxicity against human ovarian cancer A2780 and OVCAR-3 cells as an effective
inhibitor of cell growth and proliferation, while exerting lesser effects on non-tumorigenic IOSE-144 cells. Further study in
the more sensitive OVCAR-3 cell line showed that it could potently induce cell apoptosis (Annexin V-FITC assay), G2/M cell
cycle arrest (PI staining analysis) and also dose-dependently inhibit OVCAR-3 xenograft tumors’ growth on female athymic
nude mice (BALB/c, nu/nu). Mechanistic studies (both in vitro and in vivo) revealed that FBA-TPQ might exert its activity
through Reactive Oxygen Species (ROS)-associated activation of the death receptor, p53-MDM2, and PI3K-Akt pathways in
OVCAR-3 cells, which is in accordance with in vitro microarray (Human genome microarrays, Agilent) data analysis (GEO
accession number: GSE25317). In conclusion, FBA-TPQ exhibits significant anticancer activity against ovarian cancer cells,
with minimal toxicity to non-tumorigenic human IOSE-144 cells, indicating that it may be a potential therapeutic agent for
ovarian cancer.
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Introduction
Ovarian cancer, accounting for about 5 percent of women’s
cancers death, is now the fifth common cancer in the U.S women
[1]. About 70% of all ovarian cancer patients are diagnosed at the
more advanced stages of the disease, leading to a poor prognosis
[2,3]. Over the past two decades, although the 5-year survival rate
for ovarian cancer patients has been substantially improved owing
to the application of successful surgery and the development or
optimization of tumoricidal drugs, the survival still remains low, at
approximately 30% [2–4]. Thus, there is an urgent need to develop
novel therapeutic agents that can be used to treat the disease.
Marine organisms are a rich source of potential lead compounds
with unique pharmacological properties [5,6]. Numerous marine
natural products with novel molecular structures and diverse
biological functions have been reported during the past decades
[7]. Makaluvamines, a class of marine pyrroloiminoquinone
alkaloids isolated from sponges of the genera Zyzzya, have been
reported to have potent in vitro and in vivo cytotoxicity against
several human cancer cell lines, and this activity was attributed to
their activity as topoisomerase II inhibitors [8–14]. Several other
makaluvamines have been shown to cause direct DNA damage
leading to anti-tumor effects [6,15].
We have synthesized more than 40 novel makaluvamine
analogues and systematically evaluated their anticancer activities
in breast cancer cell lines. Our data showed that the potent
makaluvamine analog, FBA-TPQ, could inhibit tumor growth
through activation of tumor suppressors, inhibition of oncogenes,
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20729and activation of the DNA damage response [6,16]. In the present
report, we expanded our study to evaluate the anti-tumor activities
of FBA-TPQ against ovarian cancer cells and tried to further
elucidate the possible mechanisms of action.
Results
The in vitro cytotoxicity of FBA-TPQ to A2780 and OVCAR-3
cells were first assessed using the MTS assay (Promega). A2780
and OVCAR-3 and human ovarian IOSE144 (Immortalized non-
tumorigenic Ovarian Surface Epithelial cells) cells were exposed to
FBA-TPQ (see Fig. 1A) at various concentrations for 48 hrs. The
viability of the A2780 and OVCAR-3 cells were significantly
decreased, with IC50 of 1780 nM (A2780) and 980 nM (OVCAR-
3) (Fig. 1B). Exposure to FBA-TPQ led to dose-dependent effects
on cell survival, inhibiting A2780 viability by 25.2%, 45.7%, and
65.8% while inhibiting OVCAR-3 cells viability by 33.9%, 56.7%,
and 73.7%, respectively, for the 0.5, 1.0 and 2.5 mM concentra-
tions, respectively, (Fig. 1, p,0.05). On the other hand, the
IOSE144 cells were much less sensitive to FBA-TPQ treatment,
with an IC50 over 10 mM (Fig. 1B, p,0.01). Exposure to FBA-
TPQ decreased the viability of IOSE-144 cells by 2.7%, 7.7%, and
25.6%, respectively, for the 0.5, 1.0 and 2.5 mM concentrations
(Fig. 1B), indicating that FBA-TPQ has selective activity against
Figure 1. FBA-TPQ preferentially decreases cell viability and growth of A2780 and OVCAR-3 cells but not normal IOSE-144 cells. A,
Chemical structure and molecular formula of FBA-TPQ; B, Cell viability (MTS) assay of human ovarian carcinoma cells (A2780 and OVCAR-3) and
nontumorigenic OSE cells (IOSE144) after a 48 h incubation with FBA-TPQ; C&D&E, Cell growth inhibition after 0, 24, 48 or 72 h exposure of A2780 (C),
OVCAR-3 (D) and IOSE-144 (E) cells to FBA-TPQ(at concentrations of 0, 0.5, 0.75 and 1.0 mM). All values are representative of at least three
independent experiments with similar results, and are presented as the percentage of cell growth inhibition, where vehicle-treated cells were
regarded as 100% viable (0% growth inhibition).
doi:10.1371/journal.pone.0020729.g001
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OVCAR-3 cells proliferation in a dose-dependent manner (Fig. 1C
and 1D), while its anti-proliferative effects were much less evident
in the IOSE144 cells treated with the same concentrations of FBA-
TPQ (Fig. 1E). In fact, FBA-TPQ significantly inhibited A2780
and OVCAR-3 cells proliferation beginning at the 0.5 mM
concentration (Fig. 1C and 1D, p,0.05) while there was no
significant inhibition in the IOSE-144 cells at any of the
concentrations (up to 1 mM; Fig. 1E, p.0.05). These data suggest
that FBA-TPQ can selectively inhibit A2780 and OVCAR-3
ovarian cancer cell growth and proliferation while exerting less
potent effects on non-tumorigenic IOSE144 cells.
Since FBA-TPQ dramatically reduced OVCAR-3 cell survival
and proliferation, we next chose this more FBA-TPQ-sensitive
ovarian cancer cell line to investigate the underlying mechanism
responsible for the decrease in cell viability exposed to the
compound. First, we evaluated whether FBA-TPQ can induce
OVCAR-3 cells’ apoptosis. As shown in Fig. 2A and 2B, FBA-
TPQ strongly induced apoptosis in a dose-dependent manner
during 24 hr exposure. At 0.5 mM concentration, FBA-TPQ
increased apoptosis in the OVCAR-3 cells to 260% (of the control
cells), while at 1.5 mM concentration, the apoptosis index was
increased by nearly 4-fold (Fig. 2B, p,0.05). The pro-apoptotic
effects were more profound at the concentration of 2.5 mM
(apoptotic index increased to about 600% compared to control)
(Fig. 2B, p,0.01). To conclude, our data demonstrated that FBA-
TPQ can induce significant apoptosis in the OVCAR-3 cells in a
dose-dependent manner.
We also investigated whether FBA-TPQ has any effect on cell
cycle progression in OVCAR-3 cells. For this assay, we decreased
the FBA-TPQ incubation time to 12 h to to avoid the high
apoptosis induction. As illustrated in Fig. 2C and 2D, after a 12-h
treatment, FBA-TPQ induced significant increases in the number
of cells in the G2/M-phase at the 1500 nM (21.6% increase of
control, p,0.05) and 2.5 mM (30.0% increase of control, p,0.05)
concentrations. In addition, FBA-TPQ treatment also led to a
significant increase in the number of cells in the S-phase at the
2.5 mM concentration (Fig. 2D, p,0.05). As summarized in
Fig. 2D, FBA-TPQ caused a concomitant, dose-dependent,
decrease in the number of cells in the G0/G1-phase (p,0.01).
Taken together, our data suggest that the inhibitory effects of
FBA-TPQ on cell viability and growth may be associated with its
induction of apoptosis and cell cycle arrest.
In our previous work, we reported that FBA-TPQ may exert
DNA damage in breast cancer cells [6]; here, we investigated
whether FBA-TPQ can induce cellular ROS stress and cause
oxidative damage to the DNA in ovarian cancer cells. In this assay,
we decreased the incubation time again to 4 h (to avoid ROS
attenuation) while increased the serial concentrations to 0, 1.0, 2.0
and 3.0 mM (to produce quick ROS induction for grabbing the
image). As shown in Fig. 3A and 3B, after 4 hrs of incubation, FBA-
TPQ induced a significant (p,0.05) dose-dependent increase in
cellular ROS production in OVCAR-3 cells (Fig. 3B). Based on our
observationthatFBA-TPQcould induceapoptosis,weevaluatedthe
mitochondria trans-membrane potential (DYm) dissipation as an
indicator of mitochondrial membrane disruption and cells undergo-
ing apoptosis. Using the JC-1 dye, we observed that FBA-TPQ
treatment resulted in a significant (p,0.05) dose-dependent DYm
dissipation(dose-dependent reduction of JC-1 aggregatesisindicated
by decreased ratios of red/green fluorescence intensity) after 24 hrs
exposure (Fig. 4A and 4B). Taken together, these results provide
evidence that FBA-TPQ induces elevated cellular ROS production
and loss of mitochondria membrane potential, initiating the
endogenous ROS stress-triggered early cellular apoptosis pathway.
To further define the effects of FBA-TPQ on cell apoptosis, cell
cycle progression, and proliferation, we investigated the level of
expression of a panel of proteins involved in these pathways in
OVCAR-3 cells (see Fig. 3C). After a 24-h treatment of FBA-TPQ
(with concentrations of 0, 0.25, 0.75 and 1.0 mM), we observed a
dose-dependent increase in the expression of cleaved- Poly (ADP-
ribose) Polymerase (PARP) and Caspase-3, as well as Bax, with a
concomitant dose-dependent decrease in Bcl-2. We further
investigated the possible mechanisms responsible for the anti-
proliferative and cell cycle regulatory effects of FBA-TPQ. As
above, we evaluated the expression level of various proteins
associated with proliferation and cell cycle progression, and
observed the down-regulation of Cdc25c, CyclinB1 and Cyclin
Dependent Kinase (CDK)1, which are responsible for the G2/M
phase transition, and found an increase in the expression of Rb,
p21 and p27 proteins, as well as a decrease in the E2F1 protein, all
of which are involved in cell proliferation (Fig. 3C). Moreover, our
data showed that FBA-TPQ can decrease the expression and
activation (indicated by phosphorylation) of Akt, as well as its
upstream kinase PI3K’s catalytic subunit PI3K-110a. We further
evaluated the regulatory effects of FBA-TPQ on p53, and found
that FBA-TPQ activated p53, with an accompanying down-
regulation in MDM2 expression (see Fig. 3C), and increased
cleavage of PARP and Caspases-3. These findings are indicative of
apoptosis and/or anti-proliferative and cell cycle inhibitory effects.
As demonstrated in Fig. 3C, we also observed a dose-dependent
up-regulation of Fas, indicating that the death receptor pathway,
together with p53, may play a major role in the response to FBA-
TPQ and its stimulation of ROS stress. Taken together, we can
conclude that FBA-TPQ may exert its in vitro effects through the
ROS-associated, and PI3K-Akt-mediated/p53-MDM2-related
cell proliferation, apoptosis and cell cycle progression associated
pathways (Fig. 5).
We established the OVCAR-3 tumor xenograft model to
evaluate the in vivo anti-tumor activity of FBA-TPQ. The
compound was administered 5 days a week i.p. at a dose of
1 mg/kg or 10 mg/kg. Therapeutic effects were evaluated by
examining tumor growth. As shown in Fig. 4C, FBA-TPQ exhibits
significant (p,0.01) tumor inhibition in a dose-dependent manner.
The significant tumor growth inhibitory effects started to be
evident on the ninth day of treatment (p,0.05). After 18 days of
treatment, FBA-TPQ resulted in 20.5% tumor growth inhibition
(compared to the control group) at the lower 1 mg/kg dose, and
69.4% tumor growth inhibition at the higher 10 mg/kg dose
(Fig. 4C, p,0.01). Moreover, although the mice receiving the
10 mg/kg dose experienced a slight loss in body weight, there
were no significant differences in body weight loss (p.0.05)
between the three groups, indicating that FBA-TPQ may have an
acceptable safety profile (Fig. 4D).
To validate the in vitro findings about the mechanism of action of
FBA-TPQ, we further assessed the in vivo expression level of the
proteins examined in the cultured cells (Fig. 4E). Consistent with
the in vitro data, the protein expression patterns in the treated
xenograft tumor tissue were essentially the same as the cellular
observations (see Fig. 3C and Fig. 4E), confirming that the anti-
tumor effects of FBA-TPQ are, at least partially mediated through
the induction of ROS stress and subsequent mitochondrial
collapse, which lead to alterations in cellular cascades that are
involved in apoptosis, cell proliferation and cell cycle progression.
Discussion
The present study is the first to systematically investigate the
novel synthetic makaluvamine analog FBA-TPQ’s in vitro and in
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that FBA-TPQ exerts its anti-cancer activities on A2780 and
OVCAR-3 cells by inhibition of cell growth and proliferation.
Further study use the more sensitive OVCAR-3 cell line revealed
that it could induce cell apoptosis and cell cycle arrest. Such
functional outcomes are achieved through a cascade of reactions
within these pathways, including induction of cellular ROS stress,
death-receptor activation and mitochondrial collapse, and subse-
quent regulation of p53-MDM2 and PI3K-Akt associated
pathways.
In our previous studies, we showed that FBA-TPQ is the most
potent makaluvamine analog with regard to induction of DNA
damage, apoptosis, cell cycle arrest and proliferation inhibition in
breast cancer cells [6]. However, the possible underlying
mechanisms for these anti-tumor activities and the compound’s
potential application for other cancer types had not been
elucidated. The focus of the current study was to determine
whether FBA-TPQ could represent a promising candidate for
future anti-cancer drug development, and to further elucidate its
mechanism(s) of action.
We initially observed that FBA-TPQ exerts significant cytotoxicity
and cell proliferation inhibition effects towards A2780 and OVCAR-
3 cells. Subsequent evaluation revealed a dose-dependent effect of
FBA-TPQ on OVCAR-3 cells apoptosis, and cell cycle progression
(G2/M phase cell cycle arrest). These observations were further
supported by expression profiling of related proteins in OVCAR-3
cells using Western blotting. In an attempt to explore the
mechanism(s) of action underlying the observed biological activities
of FBA-TPQ, we found that FBA-TPQ can induce cellular ROS
stress and subsequent mitochondrial collapse, providing a potential
explanation for the cascade triggering the in vitro anticancer effects,
including apoptosis. Next, we evaluated the in vivo activity of FBA-
TPQ in the OVCAR-3 ovarian cancer xenograft model, and showed
that FBA-TPQ can again exert potent tumoricidal activity, with up to
69.4% tumor growth inhibition at the 10 mg/kg dose. We
systematically (both in vitro and in vivo) evaluated its underlying
mechanism(s) of actions, and our in vivo studies confirmed that FBA-
TPQ exerts its potent anti-tumor effects mainly by affecting cell
proliferation, inducing cell apoptosis and cell cycle arrest.
The cleavage of PARP and procaspase-3 are the well-
documented indicators of apoptosis [18,19]. Members of the
Bcl-2 family, such as Bcl-2 and Bax, are known critical regulators
responsible for cell survival/apoptosis [20–22]. We have demon-
strated a dose-dependent cleavage of PARP and procaspase-3, as
well as a dose-dependent decrease in the Bcl-2/Bax ratio in FBA-
TPQ-treated cells and tumors, providing evidence that FBA-TPQ
induces apoptosis. Based on our previous data showing that FBA-
TPQ may act as a DNA damaging agent, we evaluated the ROS
level in OVCAR-3 cells after FBA-TPQ incubation, as oxidation
(together with methylation, depurination and deamination) caused
by ROS stress can contribute to DNA damage [23]. Indeed, we
observed a dose-dependent increase in the cellular ROS level, as
well as a dose-dependent dissipation of the mitochondrial
membrane potential. Since the loss of mitochondrial membrane
potential is considered an early event in apoptosis [18,24], we may
conclude that FBA-TPQ triggers the observed apoptosis in
OVCAR-3 cells by inducing an elevated level of cellular ROS,
leading to subsequent mitochondrial membrane collapse [23,24].
Cells utilize the cell cycle checkpoints to ensure proper cell cycle
execution in order to protect dividing cells from potentially fatal
DNA damage [25,26]. Cells may be arrested in the G2/M phase
in order to undergo DNA repair or apoptotic cell death [26,27].
To further investigate the effects of FBA-TPQ on cell cycle arrest
as a result of its induction of DNA damage, we evaluated its
modulation of the expression of key proteins involved in G2/M
signaling, and observed a dose-dependent decrease in the
expression of CDC25C and CDK1/Cyclin B1, whose activation
are key for G2/M progression [26,28,29]. This confirms that FBA-
TPQ promotes G2/M arrest of OVCAR-3 cells following ROS-
induced damage.
Activation of p53 is a major mechanism of action for many
DNA damaging agents [6]. We observed a dose-dependent
increase in mutant-p53 expression in OVCAR-3 cells, which is
consistent with our previous report that cells respond to FBA-TPQ
damage regardless of their p53 status [6]. We also observed down-
regulation of MDM2 and a concomitant decrease in E2F1, and
increased expression of Rb, p21 and p27 [30,31], indicating that
the activation of the p53-MDM2 feedback loop is likely
responsible for the FBA-TPQ treatment-induced increase in the
apoptosis and cell cycle arrest and the decrease in cell growth and
proliferation in A2780 and OVCAR-3 cells. The Akt signaling
pathway plays critical roles in regulating cell survival [32,33]. The
activation of Akt by PI3K (phosphoinositide-3-OH-kinase) kinase
can regulate transcriptional factors that are responsible for pro-
and anti-apoptotic proteins, as well as growth factors for survival in
response to extracellular stimuli or damage [32]. Phosphorylated
Akt (p-Akt) is reported to be able to hinder the p53-dependent
apoptosis and growth suppression by phosphorylating MDM2
[34]. Our data showed a dose-dependent decrease in p-Akt (and t-
Akt) and its upstream activator PI3K (catalytic subunit) and an
increase in Fas (death receptor), suggesting that the FBA-TPQ
stimulus -suppresses the PI3K-Akt (p-Akt) pathway and phosphor-
ylates MDM2 to regulate the expression of growth factors (E2F1,
Rb, p21 and p27, etc.) or apoptotic (PARP, Bcl-2, Bax and
caspase-3, etc.) and cell cycle related (CDC25C,CDK1 and Cyclin
B1, etc.) proteins, resulting in the compound’s sustained anti-
cancer effects.
Considering the high mortality rate of ovarian cancer [1–4], it is
necessity to explore new agents that can act via novel mechanisms
of action to improve ovarian cancer therapy. The present study
suggests that the most effective makaluvamine analog, FBA-TPQ,
may be a novel and promising anti-ovarian cancer agent, in that it
can preferentially and potently inhibit ovarian cancer OVCAR-3
cell (but not non-tumorigenic OSE cell) growth. According to our
in vitro and in vivo data, we believe that FBA-TPQ can inhibit
ovarian carcinoma growth by triggering the Fas-related/ROS-
associated, and PI3K-Akt mediated/p53-MDM2-related increase
in cellular apoptosis and cell cycle arrest and the decrease in cell
proliferation (Fig. 5). These findings were confirmed at the protein
level in in vitro and in vivo, and were consistent with our microarray
data analysis (see Text S1, Fig. S1, Tables S1, S2, S3), that FBA-
TPQ exerts its activity mainly through its induction of ROS and
Figure 2. FBA-TPQ induces dose-dependent apoptosis and G2/M cell cycle arrest in OVCAR-3 cells. A, Apoptosis of OVCAR-3 cells
treated with serial concentrations of FBA-TPQ for 24 hr; B, Data summary and analysis of the apoptotic index (Q1 reflects necrosis, Q2 reflects late
apoptosis, Q3 reflects healthy cell population not affected by apoptosis or necrosis while Q4 reflects early apoptosis). C, Cell cycle evaluation of
OVCAR-3 cells treated with serial concentrations of FBA-TPQ for 12 hr; D, Data analysis of cells presented as the percent distribution of a specific
phase (*, p,0.05 versus the control, **, p,0.01 versus the control, respectively). Data are representative of values from at least three independent
experiments with similar results.
doi:10.1371/journal.pone.0020729.g002
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signaling pathway’ and ‘phosphatidylinositol signaling system’
(e.g., PI3K-Akt), as well as its negatively regulation of CDK (e.g.,
CDK1 and the related CDC25C and CyclinB1).
In conclusion, our study demonstrated that FBA-TPQ can exert
potent cytotoxicity and cell proliferation inhibition effects towards
A2780 and OVCAR-3 cells. Except for the induction of apoptosis,
it can also induce cell cycle arrest and inhibit OVCAR-3 xenograft
Figure 3. FBA-TPQ induces cellular ROS and regulates the p53-MDM2, and PI3K-Akt mediated pathways. A&B, FBA-TPQ induces dose-
dependent ROS stress in OVCAR-3 cells (A, the dose-dependent increase in the ROS as indicated by CM-H2DCFDA; B, Data summarized as the
percentage compared with the control). C, Western blot analysis of cellular protein expression levels of the related pathway, indicating FBA-TPQ may
take effects through the ROS-accompanied, and PI3K-Akt-mediated/p53-MDM2-related cell proliferation, apoptosis and cell cycle progression
associated pathway on OVCAR-3 ovarian cancer cell lines after 24 h exposure (at 250,750 and 1000 nM concentrations).
doi:10.1371/journal.pone.0020729.g003
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PI3K-Akt mediated/p53-MDM2-related cell proliferation and
apoptosis and cell cycle progression-associated pathways (illustrat-
ed in Fig. 5). However, the precise mechanism(s) of the compound,
and whether it exerts the same effects in other tumors types have
yet to be well elucidated. In the future, the present study, together
with our previous reported findings [6], will surely improve our
understanding about the mechanisms of action of makaluvamine
Figure 4. FBA-TPQ causes dissipation of the mitochondrial membrane potential and exerts potent tumor growth inhibition. A and B,
Fluorescence intensity (JC-1 produces red fluorescence within the mitochondria as JC-1-aggregates while emits green fluorescence when leaks into
the cytoplasm as JC-1-monomers; Fluorescence intensity shift between green and red is proportional to the DYm change) values of JC-1 dye at
specific excitation wavelengths and the corresponding ratio of Red/Green change (% of the control) after exposure to FBA-TPQ for 24 h (*, p,0.05
versus the control). C&D, Inhibition of tumor growth in mice bearing OVCAR-3 xenograft tumors (*, p,0.05 versus the control; **, p,0.01 versus the
control), and the corresponding body weight changes during the treatments (p.0.05); E, Western-blot analysis of proteins (of the mice xenograft
tumors after FBA-TPQ treatment of 0, 1 or 10 mg/kg dosage) involved in the FBA-TPQ-triggered, and PI3K-Akt mediated/p53-MDM2-related pathway.
doi:10.1371/journal.pone.0020729.g004
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development of FBA-TPQ as a novel anti-cancer agent.
Materials and Methods
Compounds and Reagents
All chemicals were all of analytical grade. FBA-TPQ was a kind
gift from Professor Sadanandan Velu (UAB, Birmingham, AL,
USA). Propidium iodide (P4170) was bought from Sigma-Aldrich,
Inc. (St. Louis, MO, USA). The JC-1 dye (5,59,6,69-tetrachloro-
1,19,3, 39-tetraethylbenzimidazolylcarbocyanine iodide) (T-3186),
TRIZOL reagent and CM-H2DCFDA [5-(and-6)-chloromethyl-
29,7 9- dichlorodihydrofluorescein diacetate acetyl ester] (C6827)
were purchased from Invitrogen-Molecular Probes Co. (City,
State, USA). The CellTiter 96H AQueous One Solution (G3580)
Cell Proliferation Assay (MTS assay) kit was purchased from
Promega Co.,Ltd. (Madison, WI). The DC protein assay kit (500-
0113) was obtained from Bio-Rad (Hercules, CA, USA), and the
ECL plus system was purchased from Amersham Pharmacia
Biotech (Buckinghamshire, UK). All cell culture supplies were
obtained from Invitrogen-Gibco Co. (City, State, USA). The Anti-
human MDM2 antibody was obtained from CalbiochemH of
EMD Chemicals Inc. (Darmstadt, Germany), the Caspase-3
(8G10) antibody was purchased from Cell Signaling Technology,
Inc. (Danvers, MA, USA), and the anti-human b-actin (AC-74)
antibody was obtained from Sigma-Aldrich, Inc. (St. Louis, MO).
Anti-human p53 (SC-98), Fas (SC-8009), PI3K110a (SC-7189),
PI3K85a (SC-423), AKT (SC-8312), p-AKT (SC-7985-R), PARP
(H-250, SC-7150), Bax (SC-493), Bcl-2 (SC-509), Rb (SC-50), p21
(SC-817), p27 (SC-528), E2F1 (SC-193), CDK1 (SC-8395), Cyclin
B1 (SC-595), and CDC25C (SC-13138) antibodies, together with
all secondary antibodies (anti-mouse, anti-goat and anti-rabbit
immunoglobulin G) were purchased from Santa Cruz Biotech-
nology, Inc. (Santa Cruz, CA, USA).
Cell Lines and Cell Culture
Human ovarian carcinoma A2780 and OVCAR-3 cells and
human ovarian IOSE144 (Immortalized non-tumorigenic Ovarian
Surface Epithelial cells) that were originally obtained from the
AmericanTypeCultureCollection(ATCC,Manassas,VA)weregifts
from Dr. Jing Fang (Institute for Nutritional Sciences, Shanghai,
China). All cells were cultured in RPMI 1640 medium supplemented
with 10% FBS and 1% penicillin/streptomycin according to the
ATCC’s instructions. FBA-TPQ was dissolved in DMSO then
diluted in cell culture media (,0.1%, final incubation concentration).
Cell Viability Assay
Cell growth and viability were determined by the MTS assay
using the CellTiter 96H AQueous One Solution Cell Proliferation
Assay kit (G3580, Promega). In brief, 4610
3 cells (per well) were
Figure 5. Cartoon of the possible mechanisms of action by which FBA-TPQ excerts its anticancer activities.
doi:10.1371/journal.pone.0020729.g005
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FBA-TPQ (dissolved in DMSO ,0.1%, final concentration) at
serial concentrations (0, 100, 500, 750, 1000, 1500 and 2500 nM),
or were treated for various times (0, 24, 48 and 72 hr) with FBA-
TPQ at concentrations of 0, 500, 750 and 1000 nM. After
24,72 hrs treatment, 20 mL of MTS solution was added to each
well. Plates were incubated for an additional 2,4 hrs at 37uC,
after which the absorbance at 490 nm was recorded using a
SpectraMax
190 microplate reader (Molecular Devices, USA) to
calculate the cell survival percentages.
Detection of Apoptosis
Cell apoptosis was detected via an Annexin V-FITC kit
purchased from BioVision, Inc [6,17]. Briefly, 1610
6 cells were
seeded in 6-cm dishes and treated with the test compound (FBA-
TPQ) at 0.5, 1.5 and 2.5 mM for 24 hr prior to analysis. The
floating and trypsinized adherent cells were collected and prepared
for detection according to the manufacturer’s instructions. Samples
were analyzed with a FACSAria
TM flow cytometer (Becton
Dickinson, USA) after incubation in the dark at room temperature
for 5 min. Cells positive for early apoptosis (Annexin V-FITC
stained only,seeQ4inFigure2A)and forlateapoptosis(AnnexinV-
FITC and PI stained, see Q2 in Figure 2A) were combined.
Cell Cycle Analysis
Propidium iodide (PI) staining was performed to determine the
effects of FBA-TPQ on the cell cycle [6]. In brief, 6610
5 cells that
wereseededin6-cmdisheswereexposed toFBA-TPQ(at0,0.5,1.5
and 2.5 mM) and incubated for 12 hrs prior to analysis. Cells were
trypsinized, washed with PBS and fixed in 1 mL 70% ethanol
(700 mL 100% ethanol added to 300 mLP B S )a t4 uC overnight,
followed by centrifugation (3000 rpm, 5 min), incubation with
RNase (100 mg/ml) and staining with propidium iodide (50 mg/ml)
for 15 minutes in the dark. The DNA content was analyzed by a
Cell Lab Quanta
TM SC flow cytometer (Beckman Coulter, USA).
Measurement of Reactive Oxygen Species (ROS)
The production of ROS was measured using 5-(and-6)-
chloromethyl-29,7 9- dichlorodihydrofluorescein diacetate acetyl
ester (CM-H2DCFDA). Briefly, Cells (,7610
5) were seeded in 6-
cm dishes and exposed to FBA-TPQ for 4 hours at serial
concentrations (0, 1.0, 2.0 and 3.0 mM), after which the cells
were harvested and washed with PBS once, then incubated with
5 mM CM-H2DCFDA (in DMSO) for 30 min at 37uC in phenol-
red-free RPMI 1640 medium. After the removal of CM-
H2DCFDA, cells were washed with PBS again and immediately
transferred (in PBS) to a FACSAria
TM flow cytometer (Becton
Dickinson, USA) for assessment of ROS production.
Mitochondrial Membrane Potential (DYm) Quantitation
JC-1 dye was used to quantify the effects of FBA-TPQ on the
mitochondrial membrane potential, as described previously [17].
OVCAR-3 cells were seeded in 24-well plates (,4610
4 cells per
well) and incubated with FBA-TPQ at serial concentrations (0,
250, 750 and 1000 nM) for 24 h. Then the cells were incubated
with 10 mg/mL of JC-1 dye in RPMI 1640 at 37uC in the dark for
15 min. After removal of the JC-1 dye, cells were trypsinized and
washed with PBS. Aliquots of 100 mL cell suspensions from the
different concentrations were transferred to black 96-well plates.
The pure red and green fluorescence intensity was measured (for
red fluorescence: Ex=550 nm, Em=600 nm; for green fluores-
cence: Ex=485 nm, Em=535 nm), via a fluorescence plate
reader (Flexstation II 384, Molecular Devices). The ratios of
red/green fluorescence intensity (% of control) were calculated.
JC-1 staining quantitatively indicated the DYm change by shifting
the pure fluorescence intensity.
Western Immunoblotting Analysis
Immunoblotting was accomplished as described previously
[6,17]. For the in vitro studies, Cells were cultured and exposed
to various concentrations of FBA-TPQ for 24 hr, then were
collected and lysed with RIPA buffer (#9806, Cell Signaling).
After centrifugation at 13,000 rpm for 15 min at 4uC, the
supernatant was removed and kept for analysis. The total protein
concentrations were assessed using a Bio-Rad protein assay kit
(Hercules, CA). Aliquots containing identical amounts of protein
were fractionated by SDS-PAGE, then were transferred to
methanol pre-activated-PVDF membranes (Millipore, Bedford,
MA). Membranes were blocked for one hour and sequentially
incubated with primary (4uC, overnight) and secondary antibody
(one hour at room temperature), then bands of the proteins of
interest were visualized using the ECL plus system from
Amersham Pharmacia Biotech (Buckinghamshire UK).
Mouse Xenograft Model of Ovarian Cancer and In Vivo
Chemotherapy
The tumor xenograft model was established as reported
previously [6,17]. The 5-week-old female athymic nude mice
(BALB/c, nu/nu) were purchased from the Shanghai Experimen-
tal Animal Center (Shanghai, China). Animal studies were
approved by the Institute for Nutritional Sciences (Protocol
approval number is 2010-AN-2, with the Protocol title ‘‘In vivo
and in vitro anticancer activity evaluation and molecular
mechanism study of synthetic Makaluvamine Analog for ovarian
cancer therapy’’ and Protocol expiration date ‘‘March 1st, 2013’’).
Briefly, OVCAR-3 cells were harvested and resuspended in
serum-free RPMI 1640 medium containing 20% (v/v) Matrigel
(BD Biosciences, Bedford, MA). Aliquots of cells (,5610
6 cells/
0.15 mL) were injected subcutaneously into the left inguinal area
of the mice. The tumor growth and body weight of the mice were
monitored every other day. Tumor mass (weight in g) was
determined by the formula 1/2a6b
2 where ‘‘a’’ is the long
diameter and ‘‘b’’ is the short diameter (in cm). Mice bearing
palpable tumors (about one week after tumor cell inoculation)
were randomly divided into control and treatment groups (5 mice/
group). FBA-TPQ was dissolved in Cremophor EL:Ethanol:Saline
(5:5:90, v/v/v) and administered (via i.p. injection) at doses of 1
and 10 mg/kg (5 days/week for two and half weeks). The control
group received saline only. Mice were sacrificed with CO2 gas on
Day 18; tumors were carefully excised, and homogenized with
RIPA buffer (100 mg tumor tissue/1 ml RIPA) in preparation for
immunoblotting analysis as described above.
Statistical Analysis
All of the values in the present study are reported as the means
6 SD from at least three independent experiments. One-way
ANOVA was used to test the statistical differences for single group
analysis, followed by Tukey’s multiple comparisons. Two-way
ANOVA was used for grouped analysis of statistical differences,
followed by Bonferroni post-tests.
Supporting Information
Figure S1 Microarray data support the possible molec-
ular mode of action of FBA-TPQ. A, GO category of the up-
regulated genes based on biological processes for differentially
expressed genes (p-value,0.05 and FDR,0.05 were used as a
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PLoS ONE | www.plosone.org 9 June 2011 | Volume 6 | Issue 6 | e20729threshold to select significant GO categories; LgP is the logarithm
of the p-value); B, KEGG pathway analysis of significant pathways
for differentially up-regulated genes (p-value,0.05 and
FDR,0.05 were used as a threshold to select significant KEGG
pathways; LgP is the logarithm of the p-value). C, Pathway-net
indicating the interactions of KEGG pathways (the arrow shows
how the signals flow from the source pathway to the target
pathway; the red and blue balls represent the up-regulated or
down-regulated pathways; the red ball with a blue ring indicates a
critical pathway that is both up-regulated and down-regulated).
(TIF)
Table S1 Significant GOs up-regulated by FBA-TPQ.
(DOC)
Table S2 Significant pathways up-regulated by FBA-
TPQ.
(DOC)
Table S3 The interaction net of significant pathways.
(DOC)
Text S1 Supplemental data.
(DOC)
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